Expressive

rs113897301 - ADAM19

Magnitude 2.2 · 1 study on file

Reported associations

  • Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis - Unknown journal (n.d.) · Unknown authors · PubMed 28166215

    [INTRO] Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality worldwide. We performed a genetic association in 15,256 cases and 47,936 controls, with replication of select top results (P < 5×10−6) in 9,498 cases and 9,748 controls. In the combined meta-analysis, we identified 22 loci at genome-wide significance, including 13 new associations with COPD. Nine of these 13 loci have been associated with lung function in general population samples; however, 4 (EEFSEC, DSP, MTCL1, and SFTPD) are novel. We noted 2 loci shared with pulmonary fibrosis (FAM13A and DSP) but with opposite risk alleles for COPD. None of our loci overlapped with genome-wide associations for asthma; however, one locus has been implicated in the joint susceptibility to asthma and obesity. We also

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • Genetic COPD susceptibility and prevention strategy Moderate

    ADAM19 variant increases COPD risk independent of smoking status; personalized risk assessment and prevention approach recommended

Lifestyle

  • Smoking and secondhand smoke exposure Moderate

    Smoking is primary COPD risk factor; genetic variant confers additive independent risk, making avoidance critically important

    If current smoker, prioritize cessation support; minimize secondhand smoke and occupational respiratory hazard exposure

Screening

  • Spirometry (lung function testing for FEV1/FVC) Moderate

    ADAM19 variant associated with 20-23% increased COPD odds; early detection of airflow limitation enables timely intervention

    Discuss with healthcare provider about baseline spirometry at age 40-45 or earlier if smoking exposure or respiratory symptoms present